EP0572494B1 — Composition for use in transdermal administration
Assigned to Commonwealth Scientific and Industrial Research Organization CSIRO · Expires 1999-08-25 · 27y expired
What this patent protects
The invention provides a composition for transdermal administration of a biologically active agent comprising said biologically active agent and a pharmaceutically acceptable carrier wherein said biologically active agent is present at a concentration above its solubility limit i…
USPTO Abstract
The invention provides a composition for transdermal administration of a biologically active agent comprising said biologically active agent and a pharmaceutically acceptable carrier wherein said biologically active agent is present at a concentration above its solubility limit in said carrier at ambient conditions and wherein there are sufficient fine solid particles of said agent dispersed through said carrier to substantially facilitate the transdermal transfer of said composition. The invention also provides a method of preparation of such compositions.
Drugs covered by this patent
- Risperdal (risperidone) · Johnson & Johnson (Janssen)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.